title: Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism.
abstract: BACKGROUND
  Poor specificity of face-value endpoints and the poor sensitivity of gross clinical examination may have militated against demonstrating prophylaxis by selegiline.
  
  
  METHODS
  Objective measures of the four cardinal signs were used as primary outcome criteria in a randomised, double-blind, placebo-controlled, parallel group study of selegiline monotherapy in 25 newly diagnosed elderly sufferers from idiopathic parkinsonism, stratified for sex and Hoehn and Yahr functional staging.
  
  
  RESULTS
  There was a significant interaction between time and nature of treatment with respect to rigidity. The effect of time during active treatment was highly significant: rigidity decreased by 1.3% per week. The worsening of rigidity on placebo was not statistically significant. Neuronal rescue is a possible explanation for the long term, progressive improvement produced by selegiline. No significant treatment effect was seen on the other cardinal signs. However, there was a significant quadratic time trend for arousal on active treatment suggesting tolerance to this effect.
  
  
  CONCLUSIONS
  The difference in time course between the psychostimulant and physical effects suggests more than one mode of action.
authors: Hillingdon Hospital, Uxbridge, Middlesex, UK.
authors: C
authors: C
authors: Kirollos
authors: A
authors: A
authors: Charlett
authors: S G
authors: SG
authors: Bowes
authors: A G
authors: AG
authors: Purkiss
authors: C J
authors: CJ
authors: O'Neill
authors: C
authors: C
authors: Weller
authors: J
authors: J
authors: Dickins
authors: G
authors: G
authors: Faulkner
authors: P W
authors: PW
authors: Nicholson
authors: W B
authors: WB
authors: Hunt
authors: R J
authors: RJ
authors: Dobbs
authors: S M
authors: SM
authors: Dobbs
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001143:Arousal / Q000502:physiology; D004311:Double-Blind Method; D005260:Female; D005684:Gait / Q000187:drug effects / Q000502:physiology; D006801:Humans; D018476:Hypokinesia / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D009127:Muscle Rigidity / Q000188:drug therapy / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011187:Posture / Q000502:physiology; D011597:Psychomotor Performance / Q000187:drug effects; D012107:Research Design; D012642:Selegiline / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome; D014202:Tremor / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000978:Antiparkinson Agents; D012642:Selegiline